3d:T4f0,Common

Dermatologic:Injection site reaction (pediatric, 44%), Pruritus
Endocrine metabolic:Weight decreased (10% to 29%)
Gastrointestinal:Diarrhea (10% to 22%), Gastrointestinal symptom (pediatric, 49%), Loss of appetite (24% to 32%), Nausea (25% to 43%), Vomiting (11% to 29%)
Hematologic:Neutropenia (8% to 40%)
Neurologic:Asthenia (63% to 68%), Dizziness, excluding vertigo (14% to 21%), Headache (43% to 62%), Insomnia (30% to 41%)
Other:Fatigue (pediatric, 25%), Influenza-like illness (pediatric, 91%)

Serious

Cardiovascular:Myocardial infarction
Hematologic:Hemolytic anemia (10% to 13%), Thrombotic thrombocytopenic purpura (less than 1%)
Hepatic:Hepatotoxicity, Hyperammonemia, Hyperbilirubinemia, Increased erythrocyte destruction, Liver failure, oral, in combination with peginterferon alfa-2a (2%)
Immunologic:Bacterial infectious disease, oral, in combination with peginterferon alfa-2a (less than 1%)
Psychiatric:Suicide (Less than 1%)
Respiratory:Complication of respiratory therapy procedure, Drug precipitation, Respiratory complication

3e:T43e,

Pregnant women should not administer the inhaled form of drug or be near a patient during inhalation therapy.
Adverse effects to a fetus may be caused by either male or female patients receiving this drug. Emphasize the use of reliable contraception. This applies during treatment and up to 6 months post-therapy.
This drug may cause rash, pruritus, dyspepsia, anorexia, nausea, headache, conjunctivitis, rigors, and dry mouth.
Drug may also cause insomnia, depression, and fatigue.
Patient should report signs/symptoms of severe depression and/or suicidal ideation.
Instruct patient to report signs/symptoms of respiratory deterioration, pancreatitis, hemolytic anemia, or cardiac deterioration.
Warn patient not to open, crush, or break the drug capsules, under any circumstances.
Patient should take the oral drug consistently with regard to food intake.
For inhaled form, advise patient on proper inhalation technique.
Patient should not mix inhaled form of drug with other aerosolized drugs.

3f:T460,

Inhalation
- pregnant healthcare workers should not administer; if this is unavoidable, follow proper procedures for minimizing exposure
- reconstitute powder with minimum of 75 mL sterile water for injection or inhalation (preservative-free) in the original vial and shake well; transfer to a 500 mL SPAG-2 reservoir and further dilute to a final volume of 300 mL with sterile water for injection or inhalation (preservative-free) to a concentration of 20 mg/mL
- only administer with SPAG-2 small particle aerosol generator
- do not administer as a mixture with other aerosolized medications
- inspect solution for particulate matter and discoloration prior to administration
- discard solution in the SPAG-2 unit at least every 24 hours
Oral
- pediatric patients who reach their eighteenth birthday while receiving peginterferon alfa-2b (Pegintron(TM)) and ribavirin should remain on the pediatric dosing regimen
- take with food
- (Rebetol(R)), capsules should not be opened, crushed, or broken

3a:{"drug_id":515530,"title":"Ribavirin","ind":"FDA-Labeled Indications

Hemopoietic stem cell transplant - Respiratory syncytial virus infection
Hepatitis C, chronic, Combination therapy in interferon alfa-naive patients with compensated liver disease - HIV infection
Hepatitis C, chronic, With compensated liver disease
Respiratory syncytial virus infection

Non-FDA Labeled Indications

","adult":"$3b","ped":"$3c","side":"$3d","prgnancy":"

RIVABIR 200 MG (Ribavirin - Capsule 200 MG) – Full Drug Info.